-
Mashup Score: 3Surgery As Needed for Oesophageal Cancer - 2 - Full Text View - ClinicalTrials.gov - 11 month(s) ago
Surgery As Needed for Oesophageal Cancer – 2 – Full Text View.
Source: classic.clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study - PubMed - 11 month(s) ago
Dutch Cancer Society.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@NiuSanford Pre-SANO which explored diagnostic strategies after CRT to assess ideal response assessment which correlated cCR with pCR https://t.co/ZuTzDdHqoa
-
-
Mashup Score: 1Sexual dysfunction following surgery for rectal cancer: a single-institution experience - PubMed - 12 month(s) ago
Although much focus is placed on oncological outcomes for rectal cancer, it is important to assess quality of life after surgery of which sexual function is an important component. This study set about to describe the prevalence of sexual dysfunction by resection type and gender among patients under …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@NiuSanford This is a great comment! To add- all patients had surgery in PROSPECT. TME is associated with considerable sexual toxicity in M and W, with dysfunction in 70+% https://t.co/LfNYWxHGMR Organ preservation with CRT can help this as can select omission of RT https://t.co/OXTa3QOxPV
-
-
Mashup Score: 5Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer - 12 month(s) ago
Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune checkpoint inhibitors has been reported to have synergic effects. …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet-
A8-4 ❓ ICI timing Ongoing trials: 📌VOLTAGE-A: LC-CRT → Nivo → surgery 📌NCRT-PD-1-LARC: LC-CRT + Tislelizumab (anti-PD-1) → surgery Primary endpoint= complete response 🔥Early results favorable with 30-50% pCR! https://t.co/hRLnPEzSj9 https://t.co/HiuUXpXetf #CRCTrialsChat
-
-
Mashup Score: 5Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial - Nature Cancer - 12 month(s) ago
Ting and colleagues report the safety and efficacy of combined radiation and immunotherapy in a phase II trial on patients with MSS colorectal or pancreatic cancer and observe that disease control correlates with higher repetitive RNA transcription.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
A8-5 A p2 trial by @aparna1024 explored combined ipi + nivo with immunostimulatory doses of RT (24 Gy in 3 fractions) to elicit enhanced systemic anti-tumoral immune response for patients with M1 CRC or PDAC. https://t.co/AboCYs8JXg #CRCTrialsChat
-
-
Mashup Score: 0Cancers - 1 year(s) ago
Cancers, an international, peer-reviewed Open Access journal.
Source: www.mdpi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ZellaZhu: You are welcome to submit articles to the new special issue of Cancers journal. https://t.co/4iRmyVFQ3O Guest editors: Dr.…
-
-
Mashup Score: 0Central liver toxicity after SBRT: An expanded analysis and predictive nomogram - PubMed - 1 year(s) ago
SBRT doses to the cHBT are associated with occurrence of HBT only in PLC patients. Limiting the dose to the cHBT to VBED1040<37cc and VBED1030<45cc when treating PLC patients with SBRT may reduce the risk of HBT.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
No major change, just no hotspots? SBRT with biliary parameters? https://t.co/OLxF5IwPlE Fractionation? https://t.co/tSjGFoA10L Alternative?
-
-
Mashup Score: 1Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases - PubMed - 1 year(s) ago
This multi-institutional, phase I/II trial demonstrates that high-dose liver SBRT is safe and effective for the treatment of patients with one to three hepatic metastases.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@NiuSanford https://t.co/dGDpEtVijZ
-
-
Mashup Score: 15
Genomic factors, in particular KRAS and TP53 mutation, may assist in patient selection and radiotherapeutic decision-making for patients with oligometastatic CRC. Prospective validation, ideally with genomic correlation of all irradiated metastases, is warranted.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
A8-3 📌Similarly, data suggest that KRAS + TP53 mutation may be associated with poorer local control & Overall Survival after oligometastasis-directed SBRT https://t.co/mThEaDmApb Figure showing local failure #CRCTrialsChat @OncoAlert #CRCSM https://t.co/6phb6WxvRx
-
A8-2 📌Similarly, data suggest that KRAS + TP53 mutation may be associated with poorer local control & Overall Survival after oligometastasis-directed SBRT https://t.co/mThEaDmApb Figure showing OS #CRCTrialsChat @OncoAlert #CRCSM https://t.co/iqkIJZDpse
-
-
Mashup Score: 3Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy - PubMed - 1 year(s) ago
A WW strategy for select rectal cancer patients who had a clinical complete response after neoadjuvant therapy resulted in excellent rectal preservation and pelvic tumor control; however, in the WW group, worse survival was noted along with a higher incidence of distant progression in patients with …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
MSKCC reported a 36% risk of DM amongst patients w/ local regrowth @JoshSmithMDPhD Emphasizes knowledge gaps in how to select pts, improve surveillance strategies, and further refine how we care for pts with the goals of preserving QoL and cancer control https://t.co/TzRZPUellW https://t.co/IzsOhdccyP
-
@NiuSanford I also agree that a selective non-op approach for esophagus adenos is likely the way of the future. The Dutch pre-SANO trial evaluated cCR response criteria. SANO and ESOSTRATE are exploring surgical omission for those with cCR. https://t.co/AaJYqV8HQT https://t.co/tVAdj7NcZv